Skip to content

Citius Pharmaceuticals, Inc.

CTXR

CIK 0001506251

← back to feed
Revenue (TTM)
$5.61M
Q2 May 2026
Net Income (TTM)
−$40.91M
+3.3% YoY Q2 May 2026
EPS Diluted (TTM)
−$3.40
+43.4% YoY Q2 May 2026
Gross Margin
—
Q2 May 2026
Operating Margin
-1,091.8%
Q2 May 2026
Net Margin
-729.1%
Q2 May 2026
Free Cash Flow (TTM)
−$28.7M
Q2 May 2026
Cash
$4.59M
Q2 May 2026
Total Debt
—
Q2 May 2026
Shares Outstanding
27.45M sh
Q2 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings